Pegilodecakin for metastatic kidney cancer

Combinations of immunotherapy and vascular endothelial growth factor (VEGF) inhibitors have been proven to effective at improving survival for people with advanced or metastatic renal cell carcinoma (RCC). However, the role of a cytokine called interleukin-10 (IL-10) has been shown to enhance immunotherapy-induced anti-cancer activity. In this phase 1 trial, the safety, tolerability and preliminary […]

read more

Effect of antibiotics on outcomes with systemic treatments for metastatic kidney cancer

The microbes in the gut (the gut microbiome) are a key part of our immune system. The use of antibiotics disrupts the gut microbiome and has been shown to make people susceptible to various illnesses. In this study, researchers investigated how antibiotics may influence response to treatment and clinical outcomes in people with metastatic renal […]

read more

Computer-designed interleukin 2 (IL 2) without the side effects?

Interleukin-2 (IL2) is a naturally-occurring biological therapy called a cytokine. Cytokines boost the immune system and have been used to treat metastatic renal cell carcinoma (RCC) since the 1990s; however, its use has been limited by toxic side effects. Recently, scientists have been working to improve IL2. Researchers at the University of Washington, US, have […]

read more

Anticancer immunotherapy that overcomes tumour resistance to immune checkpoint inhibitors

Despite some remarkable patient outcomes in recent years, most tumours do not respond to immune checkpoint inhibitors (such as nivolumab and ipilimumab), or they develop resistance to these treatments. However, researchers at Johns Hopkins University in Baltimore, USA, have developed a new class of cancer immunotherapy agents designed to disrupt the key mechanisms whereby tumours […]

read more
Showing all 4 results